INSMED Inc (INSM) stock

INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3083% above fair value

$112.58+0.99 (+0.89%)

Close on Oct 30, 2026Market cap $24.59BP/E –Yield –

Earnings

Insmed's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Feb 18, 2027

Q4 FY2026 · estimated, before the open

Revenue, Q3 FY2026

$524.40M

EPS, Q3 FY2026

-$0.46

Latest guidance

Lowered

Oct 29, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Insmed's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q4 FY2026ended Dec 31, 2026	Feb 18, 2027Expected	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Oct 29, 2026before the open	$524.40M	–	-$0.46	Release
Q2 FY2026ended Jun 30, 2026	Aug 6, 2026before the open	$425.50M	+296.2%	-$0.06	Release
Q1 FY2026ended Mar 31, 2026	May 7, 2026before the open	$306.00M	+229.7%	-$0.76	Release
Q4 FY2025ended Dec 31, 2025	Feb 19, 2026before the open	$263.80M	+152.7%	-$1.54	Release
Q3 FY2025ended Sep 30, 2025	Oct 30, 2025before the open	–	–	–	Release
Q2 FY2025ended Jun 30, 2025	Aug 7, 2025before the open	$107.40M	+18.9%	-$1.70	Release
Q1 FY2025ended Mar 31, 2025	May 8, 2025before the open	$92.80M	+22.9%	-$1.42	Release
Q4 FY2024ended Dec 31, 2024	Feb 20, 2025before the open	$104.40M	+24.7%	-$1.32	Release
Q3 FY2024ended Sep 30, 2024	Oct 31, 2024before the open	$93.40M	+18.1%	-$1.27	Release
Q2 FY2024ended Jun 30, 2024	Aug 8, 2024before the open	$90.30M	+17.0%	-$1.94	Release
Q1 FY2024ended Mar 31, 2024	May 9, 2024before the open	$75.50M	+15.8%	-$1.06	Release
Q4 FY2023ended Dec 31, 2023	Feb 22, 2024before the open	$83.70M	+41.1%	-$1.28	Release
Q3 FY2023ended Sep 30, 2023	Oct 26, 2023before the open	$79.10M	+16.8%	-$1.11	Release
Q2 FY2023ended Jun 30, 2023	Aug 3, 2023before the open	$77.20M	+18.4%	-$1.78	Release
Q1 FY2023ended Mar 31, 2023	May 4, 2023before the open	$65.20M	+22.8%	-$1.17	Release
Q4 FY2022ended Dec 31, 2022	Feb 23, 2023before the open	$59.30M	+5.7%	-$1.21	Release
Q3 FY2022ended Sep 30, 2022	Oct 27, 2022before the open	$67.70M	+44.7%	-$1.09	Release
Q2 FY2022ended Jun 30, 2022	Aug 4, 2022before the open	$65.20M	–	-$0.80	Release
Q1 FY2022ended Mar 31, 2022	May 5, 2022before the open	$53.10M	–	-$0.80	Release
Q4 FY2021ended Dec 31, 2021	Feb 17, 2022before the open	$56.10M	–	-$0.95	Release
Q3 FY2021ended Sep 30, 2021	Oct 28, 2021before the open	$46.80M	–	-$0.96	Release
Q2 FY2021ended Jun 30, 2021	Aug 5, 2021before the open	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	May 6, 2021before the open	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 25, 2021before the open	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Oct 29, 2020before the open	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Insmed's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
ARIKAYCE revenue	FY2026	$460.00M – $470.00M	–	Lowered	Oct 29, 2026
ARIKAYCE revenues	FY2026	$450.00M – $470.00M	$450.00M – $470.00M	Lowered	Aug 6, 2026

Guidance history

Every forecast Insmed put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Oct 29, 2026	ARIKAYCE revenue	FY2026	$460.00M – $470.00M	Lowered
Oct 29, 2026	BRINSUPRI revenue	FY2026	$1.35B – $1.40B	New
Aug 6, 2026	ARIKAYCE revenues	FY2026	$450.00M – $470.00M	Lowered
Aug 6, 2026	BRINSUPRI revenues	FY2026	$1.25B – $1.40B	Raised
May 7, 2026	ARIKAYCE revenues	FY2026	$450.00M – $470.00M	Lowered
May 7, 2026	BRINSUPRI revenues	FY2026	$1.00B	Raised
Feb 19, 2026	ARIKAYCE revenues	FY2026	$450.00M – $470.00M	Lowered
Feb 19, 2026	BRINSUPRI revenues	FY2026	$1.00B	New
Oct 30, 2025	global ARIKAYCE revenue guidance	FY2025	$420.00M – $430.00M	Raised
Oct 30, 2025	global ARIKAYCE revenue year-over-year growth	FY2025	+15% – +18%	New
Aug 7, 2025	global ARIKAYCE revenues	FY2025	$405.00M – $425.00M	New
May 8, 2025	global ARIKAYCE revenues	FY2025	$405.00M – $425.00M	Reaffirmed
May 8, 2025	global ARIKAYCE revenues year-over-year growth	FY2025	+11% – +17%	Reaffirmed
Feb 20, 2025	global ARIKAYCE revenues	FY2025	$405.00M – $425.00M	New
Feb 20, 2025	year-over-year growth	FY2025	+11% – +17%	New
Oct 31, 2024	global ARIKAYCE revenues	FY2024	$340.00M – $360.00M	Reaffirmed
Aug 8, 2024	global ARIKAYCE revenues	FY2024	$340.00M – $360.00M	Reaffirmed
May 9, 2024	global ARIKAYCE revenues	FY2024	$340.00M – $360.00M	Reaffirmed
Feb 22, 2024	global ARIKAYCE revenues	FY2024	$340.00M – $360.00M	New
Oct 26, 2023	global revenues for ARIKAYCE	FY2023	$295.00M – $305.00M	Reaffirmed
Aug 3, 2023	global revenues for ARIKAYCE	FY2023	$295.00M – $305.00M	Raised
May 4, 2023	global revenues for ARIKAYCE	FY2023	$285.00M – $300.00M	Reaffirmed
Feb 23, 2023	global revenues for ARIKAYCE	FY2023	$285.00M – $300.00M	New
Oct 27, 2022	global revenues for ARIKAYCE	FY2022	+30%	Reaffirmed
Aug 4, 2022	global revenues for ARIKAYCE	FY2022	+30%	Reaffirmed
May 5, 2022	global revenues for ARIKAYCE	FY2022	+30%	Reaffirmed
Feb 17, 2022	revenues for ARIKAYCE	FY2022	+30%	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.